Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne Knisely

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
Gynecologic Oncology|October 6, 2020
Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19 infectionMaria Smith, Olivia D Lara, Roisin O'Cearbhaill, et al.
Cancer|December 9, 2020
Racial disparities in patients with coronavirus disease 2019 infection and gynecologic malignancyOlivia D Lara, Maria J Smith, Yuyan Wang, et al.
Gynecologic Oncology|December 19, 2021
COVID-19 outcomes of patients with gynecologic cancer in New York City: An updated analysis from the initial surge of the pandemicOlivia D Lara, Maria Smith, Yuyan Wang, et al.
Annals of Surgery|October 19, 2020
Perioperative Morbidity and Mortality of Patients With COVID-19 Who Undergo Urgent and Emergent Surgical ProceduresAnne Knisely, Zhen Ni Zhou, Jenny Wu, et al.
Cancer|October 21, 2023
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignanciesAnne Knisely, Jibran Ahmed, Bettzy Stephen, et al.
Journal for Immunotherapy of Cancer|February 3, 2024
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinomaRodabe Amaria, Anne Knisely, David Vining, et al.
Cancer|November 27, 2023
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancerEmily M Hinchcliff, Anne Knisely, Naomi Adjei, et al.
Med (New York, N.Y.)|November 11, 2023
Transforming ovarian cancer care by targeting minimal residual diseaseAmir A Jazaeri, Rachel Grisham, Anne Knisely, et al.
Nature|September 5, 2025
Author Correction: PPP2R1A mutations portend improved survival after cancer immunotherapyYibo Dai, Anne Knisely, Mitsutake Yano, et al.
Nature|July 3, 2025
PPP2R1A mutations portend improved survival after cancer immunotherapyYibo Dai, Anne Knisely, Mitsutake Yano, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Gynecologic Oncology|October 6, 2020
Inflammatory markers in gynecologic oncology patients hospitalized with COVID-19 infectionMaria Smith, Olivia D Lara, Roisin O'Cearbhaill, et al.
Cancer|December 9, 2020
Racial disparities in patients with coronavirus disease 2019 infection and gynecologic malignancyOlivia D Lara, Maria J Smith, Yuyan Wang, et al.
Gynecologic Oncology|December 19, 2021
COVID-19 outcomes of patients with gynecologic cancer in New York City: An updated analysis from the initial surge of the pandemicOlivia D Lara, Maria Smith, Yuyan Wang, et al.
Annals of Surgery|October 19, 2020
Perioperative Morbidity and Mortality of Patients With COVID-19 Who Undergo Urgent and Emergent Surgical ProceduresAnne Knisely, Zhen Ni Zhou, Jenny Wu, et al.
Cancer|October 21, 2023
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignanciesAnne Knisely, Jibran Ahmed, Bettzy Stephen, et al.
Journal for Immunotherapy of Cancer|February 3, 2024
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinomaRodabe Amaria, Anne Knisely, David Vining, et al.
Cancer|November 27, 2023
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancerEmily M Hinchcliff, Anne Knisely, Naomi Adjei, et al.
Med (New York, N.Y.)|November 11, 2023
Transforming ovarian cancer care by targeting minimal residual diseaseAmir A Jazaeri, Rachel Grisham, Anne Knisely, et al.
Nature|September 5, 2025
Author Correction: PPP2R1A mutations portend improved survival after cancer immunotherapyYibo Dai, Anne Knisely, Mitsutake Yano, et al.
Nature|July 3, 2025
PPP2R1A mutations portend improved survival after cancer immunotherapyYibo Dai, Anne Knisely, Mitsutake Yano, et al.
Pageof 4